Lantheus (LNTH)
(Delayed Data from NSDQ)
$97.33 USD
+0.07 (0.07%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $97.39 +0.06 (0.06%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$97.33 USD
+0.07 (0.07%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $97.39 +0.06 (0.06%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
LHC Group (LHCG) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
LHC Group's (LHCG) second-quarter results benefit from organic growth in hospice admissions. However, home health admissions decline organically.
Glaukos (GKOS) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Glaukos' (GKOS) Q2 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins significantly.
McKesson's (MCK) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2023 results benefit from segmental growth.
Inari Medical (NARI) Q2 Earnings Beat, CEO Transition in 2023
by Zacks Equity Research
Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.
Lantheus Holdings (LNTH) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 27.14% and 9.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AmerisourceBergen (ABC) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter results benefit from segmental growth.
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYC
Fresenius Medical's (FMS) Q2 Earnings Miss, Revenues Top
by Zacks Equity Research
Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) second-quarter results benefit from a solid performance at Discover & Analytics Solutions business.
DexCom (DXCM) Q2 Earnings Match Estimates, Revenues Miss
by Zacks Equity Research
Despite the top line missing estimates, DexCom's (DXCM) second-quarter results reflected strong domestic and international revenue growth.
Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYX
Zacks.com featured highlights Lantheus, Skyline Champion, CTS and U.S. Silica
by Zacks Equity Research
Lantheus, Skyline Champion, CTS and U.S. Silica have been highlighted in this Screen of The Week article.
Baxter (BAX) Q2 Earnings Miss Estimates, Hilrom Adds $715 M
by Zacks Equity Research
Baxter's (BAX) second-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.
Surmodics (SRDX) Beats on Q3 Earnings, Revises FY22 View
by Zacks Equity Research
Product sales primarily drive Surmodics' (SRDX) third-quarter top-line growth. However, the company expects softer demand for its products and services in the second half of 2022.
CONMED (CNMD) Down on In-Line Q2 Earnings & Lower 2022 View
by Zacks Equity Research
CONMED's (CNMD) adjusted second-quarter earnings reflect strong segmental performance. However, unfavorable currency movement hurt sales growth. Inflationary or supply chain challenges hurt gross margin.
4 Top-Ranked Liquid Stocks to Boost Portfolio Returns in 2022
by Vaishali Doshi
Here are four top-ranked liquid stocks, Lantheus (LNTH), Skyline (SKY), CTS (CTS) and U.S. Silica Holdings (SLCA), which investors can add to their portfolio for solid returns.
What Makes Lantheus Holdings (LNTH) a Good Fit for "Trend Investing"
by Zacks Equity Research
Lantheus Holdings (LNTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Lantheus (LNTH) to Report Q2 Results: What's in the Cards?
by Zacks Equity Research
Lantheus' (LNTH) Q2 performance is likely to gain from the continued uptake of PYLARIFY and DEFINITY.
Lantheus Holdings, Inc. (LNTH) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Lantheus Holdings (LNTH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Best Growth Stocks to Buy for July 21st
by Zacks Equity Research
LNTH, PEB, and AFYA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 21, 2022.
Lantheus Holdings (LNTH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Lantheus Holdings (LNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is First Trust Small Cap Core AlphaDEX ETF (FYX) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYX
Best Growth Stocks to Buy for July 18th
by Zacks Equity Research
LNTH, AFYA, and DELL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 18, 2022.
Best Growth Stocks to Buy for July 15th
by Zacks Equity Research
: DLTR, LNTH and MRK made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 15, 2022.